Depression – Pipeline Review, H1 2017, provides an overview of the Depression (Central Nervous System) pipeline landscape.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Depression – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/260222 .
The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 14, 27, 23, 74, 15 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 17 and 8 molecules, respectively.
Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Browse the full report @ http://www.orbisresearch.com/reports/index/depression-pipeline-review-h1-2017 .
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/260222 .
4D Pharma PLC
AB Science SA
Acadia Pharmaceuticals Inc
Adamed Sp z oo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Alvogen Korea Co Ltd
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Araim Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celon Pharma SA
Domain Therapeutics SA
Eisai Co Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
H. Lundbeck A/S
Heptares Therapeutics Ltd
Hua Medicine (Shanghai) Ltd
Hyundai Pharmaceutical Co Ltd
Impel NeuroPharma Inc
INSYS Therapeutics Inc
Intas Pharmaceuticals Ltd
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
Johnson & Johnson
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Mapi Pharma Ltd
Medlab Clinical Ltd
Methylation Sciences Inc
miCure Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Navya Biologicals Pvt Ltd
Neurocrine Biosciences Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
nLife Therapeutics SL
Orexigen Therapeutics Inc
Otsuka Holdings Co Ltd
Pherin Pharmaceuticals Inc
Polleo Pharma Ltd
Protagenic Therapeutics Inc
Relmada Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sound Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Company Ltd
Tetra Discovery Partners LLC
TRImaran Pharma Inc
VistaGen Therapeutics Inc
Zhejiang Huahai Pharmaceutical Co Ltd
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact firstname.lastname@example.org